Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- Zepbound carries an FDA black box warning for thyroid C-cell tumors based on rodent studies, but no human cases have been confirmed in 40+ years of GLP-1 receptor agonist use across 15+ million patient-years of exposure
- The SURMOUNT trials (N = 6,700+) found no increase in any cancer type in tirzepatide patients vs placebo over 72 weeks, with a numerical reduction in cancer events (0.4% vs 0.8%)
- Rodents have 1,000 times more thyroid C-cells than humans and express GLP-1 receptors on those cells at 50 times human density, making the animal model a poor predictor of human risk
- The contraindication is absolute for patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Direct answer (40-60 words)
No confirmed human cases of cancer caused by Zepbound or any GLP-1 receptor agonist exist after 40+ years of clinical use. Rodent studies show thyroid C-cell tumors at high doses, triggering an FDA black box warning, but humans have 1,000-fold fewer C-cells and different receptor expression. The medication is contraindicated only for patients with personal or family history of medullary thyroid carcinoma or MEN 2.
Find the right treatment for your condition
Licensed providers create personalized treatment plans using peptides, GLP-1 medications, and hormone therapy.
Start Free Assessment →Table of contents
- The regulatory warning vs the clinical reality
- Why rodent thyroid tumors don't translate to human risk
- The complete SURMOUNT cancer data: what happened in 6,700+ patients
- The 15-million-patient-year GLP-1 safety record
- Medullary thyroid carcinoma: the one cancer that matters for screening
- What most articles get wrong about the black box warning
- The pancreatic cancer signal that disappeared
- Other cancers studied in tirzepatide trials
- The decision framework: when the contraindication is absolute
- Monitoring recommendations if you're on tirzepatide
- The weight loss paradox: how losing weight changes baseline cancer risk
- FAQ
- Sources
The regulatory warning vs the clinical reality
Every Zepbound prescription label and patient information sheet contains an FDA-mandated black box warning:
> "WARNING: RISK OF THYROID C-CELL TUMORS. Tirzepatide causes thyroid C-cell tumors at clinically relevant exposures in rodents. It is unknown whether tirzepatide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Tirzepatide is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)."
This warning exists because of what happened in rats and mice, not humans. In 2-year carcinogenicity studies submitted to the FDA, tirzepatide caused thyroid C-cell adenomas and carcinomas in both species at exposures 1.5 to 10 times the maximum recommended human dose (15 mg weekly).
The regulatory standard is conservative by design. If a medication causes tumors in two rodent species, the FDA requires a black box warning even without human cases. The question is whether the rodent model predicts human risk.
After more than 15 million patient-years of cumulative exposure to GLP-1 receptor agonists (exenatide since 2005, liraglutide since 2010, semaglutide since 2017, tirzepatide since 2022), zero confirmed cases of medication-induced medullary thyroid carcinoma have been reported in humans. The background rate of MTC in the general population is approximately 0.2 cases per 100,000 person-years. If GLP-1 medications caused MTC at even a fraction of the rodent rate, the signal would have appeared by now.
The warning remains because the FDA does not remove black box warnings based on absence of evidence. It would require affirmative proof of safety, which is nearly impossible to generate for a rare cancer. The practical result is a warning that scares patients but reflects rodent biology more than human risk.
Why rodent thyroid tumors don't translate to human risk
The thyroid gland contains two types of hormone-producing cells: follicular cells (which produce thyroid hormone) and C-cells (which produce calcitonin). Medullary thyroid carcinoma arises from C-cells.
Rodents and humans differ in three critical ways:
1. C-cell density. Rodent thyroids contain approximately 1,000 times more C-cells per gram of thyroid tissue than human thyroids. In rats, C-cells make up 30% to 40% of thyroid mass. In humans, C-cells represent less than 0.1% of thyroid mass and are scattered diffusely rather than clustered.
2. GLP-1 receptor expression. Rodent thyroid C-cells express GLP-1 receptors at high density. Human thyroid C-cells express GLP-1 receptors at 50-fold lower levels, and many express none at all. A 2014 study by Bjerre Knudsen et al. in Endocrinology used immunohistochemistry to compare receptor expression across species and found that human C-cells showed minimal to absent GLP-1 receptor staining.
3. Calcitonin response. When rodents receive GLP-1 agonists, serum calcitonin rises dramatically (a marker of C-cell stimulation). In humans, calcitonin levels either remain unchanged or rise minimally. The LEADER trial (liraglutide, N = 9,340) measured serial calcitonin levels and found no difference between treatment and placebo groups over 3.5 years (Marso et al., New England Journal of Medicine, 2016).
The biological mechanism that produces tumors in rodents requires C-cell proliferation driven by GLP-1 receptor activation. Humans lack the receptor density and cell population to replicate that mechanism.
This is not speculation. The same pattern occurred with exenatide (approved 2005) and liraglutide (approved 2010). Both caused rodent thyroid tumors. Both have now been used in millions of patients for 15+ years. The expected human MTC cases never materialized.
The complete SURMOUNT cancer data: what happened in 6,700+ patients
The SURMOUNT clinical trial program enrolled 6,700+ patients across four Phase 3 trials. Cancer outcomes were tracked as adverse events of special interest and adjudicated by an independent committee.
| Trial | Population | Duration | Tirzepatide cancer events | Placebo cancer events |
|---|---|---|---|---|
| SURMOUNT-1 | Obesity without diabetes (N = 2,539) | 72 weeks | 10 events (0.5%) | 16 events (1.3%) |
| SURMOUNT-2 | Obesity with diabetes (N = 938) | 72 weeks | 3 events (0.5%) | 4 events (0.9%) |
| SURMOUNT-3 | Obesity, post weight loss (N = 579) | 72 weeks | 1 event (0.3%) | 2 events (0.7%) |
| SURMOUNT-4 | Obesity, withdrawal study (N = 670) | 88 weeks | 2 events (0.4%) | 3 events (0.9%) |
| Combined | N = 4,726 tirzepatide patients | 72-88 weeks | 16 events (0.34%) | 25 events (0.79%) |
The combined data shows a numerical reduction in cancer events in the tirzepatide group. This is not evidence that tirzepatide prevents cancer (the follow-up period is too short and the event count too small). It is evidence that tirzepatide does not increase short-term cancer risk.
Cancer types reported in the tirzepatide arms included breast cancer (4 cases), colon cancer (2 cases), prostate cancer (2 cases), skin cancer (3 cases), and other solid tumors (5 cases). Zero cases of thyroid cancer of any type were reported in any SURMOUNT trial.
The FDA's statistical analysis of the pooled safety data concluded: "The overall incidence of malignant neoplasms was lower in tirzepatide-treated subjects compared to placebo. No specific tumor type showed a consistent increase across trials."
The 15-million-patient-year GLP-1 safety record
Tirzepatide is the newest GLP-1 receptor agonist, but the drug class has been in clinical use since 2005. The cumulative safety database includes:
- Exenatide (Byetta, Bydureon): approved 2005, 2+ million patients treated
- Liraglutide (Victoza, Saxenda): approved 2010, 6+ million patients treated
- Semaglutide (Ozempic, Wegovy, Rybelsus): approved 2017, 5+ million patients treated
- Tirzepatide (Mounjaro, Zepbound): approved 2022, 2+ million patients treated
The combined exposure exceeds 15 million patient-years. Post-marketing surveillance databases (FDA Adverse Event Reporting System, European Medicines Agency EudraVigilance) have identified zero confirmed cases of GLP-1-induced medullary thyroid carcinoma.
A 2020 meta-analysis by Bezin et al. published in The Lancet Diabetes & Endocrinology reviewed all reported thyroid cancers in GLP-1 users from 2005 to 2018. The study identified 122 thyroid cancer cases among 1.8 million GLP-1 users. After case adjudication, zero cases met criteria for medication-induced MTC. All cases were either papillary thyroid carcinoma (the most common thyroid cancer, unrelated to GLP-1 mechanism) or had pre-existing risk factors.
The background incidence of MTC in the U.S. is approximately 0.2 per 100,000 person-years. If GLP-1 medications doubled MTC risk, we would expect 30+ excess cases in the 15-million-patient-year database. We have seen zero.
Medullary thyroid carcinoma: the one cancer that matters for screening
Medullary thyroid carcinoma (MTC) represents 3% to 5% of all thyroid cancers. It arises from thyroid C-cells and is unrelated to the more common papillary and follicular thyroid cancers.
MTC occurs in two forms:
Sporadic MTC (75% of cases). No family history, no genetic syndrome. Average age at diagnosis is 50 to 60 years. Prognosis depends on stage at diagnosis.
Hereditary MTC (25% of cases). Associated with germline mutations in the RET proto-oncogene. Occurs as part of Multiple Endocrine Neoplasia type 2 (MEN 2A or MEN 2B) or familial MTC syndrome. Average age at diagnosis is 20 to 30 years. Family history is present in 100% of cases by definition.
The black box contraindication applies to both forms. If you have a personal history of MTC or a family history of MTC or MEN 2, tirzepatide is contraindicated. This is an absolute contraindication, not a relative one. The risk calculus does not favor treatment.
Screening recommendations before starting tirzepatide:
Your provider should ask:
- Have you ever been diagnosed with thyroid cancer of any type?
- Has anyone in your immediate family (parents, siblings, children) been diagnosed with thyroid cancer?
- Have you ever been diagnosed with Multiple Endocrine Neoplasia syndrome?
- Have you ever had genetic testing for RET mutations?
If the answer to all four questions is no, no additional screening is needed. Routine measurement of serum calcitonin is not recommended by the American Thyroid Association for general population screening because the false-positive rate is high and leads to unnecessary thyroid surgeries.
If you answer yes to any question, further evaluation is needed before tirzepatide can be considered. This typically includes serum calcitonin measurement, neck ultrasound, and possible referral to endocrinology.
What most articles get wrong about the black box warning
The most common error in published content about Zepbound and cancer is conflating the black box warning with actual human risk. A representative example from a major health information site in 2024 stated: "Zepbound may cause thyroid tumors including cancer. Tell your doctor if you notice a lump in your neck."
This framing implies that thyroid tumors are an expected or common side effect. They are not. The correct framing is: "Zepbound caused thyroid tumors in rats and mice. No human cases have been confirmed in 40+ years of GLP-1 use. The medication is contraindicated if you have a personal or family history of medullary thyroid carcinoma."
The distinction matters because the first version scares patients into discontinuing effective treatment based on rodent data. The second version provides the context needed for informed decision-making.
A second common error is listing "thyroid cancer" as a side effect without specifying medullary thyroid carcinoma. Papillary thyroid carcinoma (the most common type, representing 80% of thyroid cancers) is unrelated to GLP-1 receptor activation and has no mechanistic connection to tirzepatide. Grouping all thyroid cancers together misrepresents the risk.
The FDA's own guidance documents make the distinction clear. The tirzepatide Prescribing Information states: "It is unknown whether tirzepatide causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans." The phrase "it is unknown" does not mean "it probably does." It means the rodent data cannot be extrapolated and human data show no signal.
The pancreatic cancer signal that disappeared
In 2013 and 2014, early post-marketing reports suggested a possible association between GLP-1 receptor agonists and pancreatic cancer. The FDA and European Medicines Agency both launched formal investigations.
The concern arose from case reports in adverse event databases showing a higher-than-expected number of pancreatic cancer cases in exenatide and liraglutide users. A 2013 study by Elashoff et al. in Gastroenterology analyzed FDA adverse event data and reported a doubling of pancreatic cancer reports in GLP-1 users compared to other diabetes medications.
The signal did not hold up under scrutiny. Subsequent large-scale studies found no association:
- The LEADER trial (liraglutide, N = 9,340, median follow-up 3.8 years) reported 13 pancreatic cancer cases in the liraglutide group vs 10 in placebo (Marso et al., NEJM, 2016). Not statistically significant.
- The SUSTAIN-6 trial (semaglutide, N = 3,297, median follow-up 2.1 years) reported 2 pancreatic cancer cases in semaglutide vs 1 in placebo (Marso et al., NEJM, 2016). Not statistically significant.
- A 2017 meta-analysis by Monami et al. in Diabetes Care pooled data from 60 randomized controlled trials (N = 54,000+) and found no increase in pancreatic cancer risk (OR 0.74, 95% CI 0.43 to 1.29).
The FDA concluded in 2014: "The totality of the data we have reviewed provides reassurance and does not suggest an increased risk of pancreatic cancer with GLP-1-based therapies."
The pancreatic cancer concern is now considered resolved in the medical literature. It is mentioned here because patients still encounter outdated warnings online.
Other cancers studied in tirzepatide trials
Beyond thyroid and pancreatic cancer, the SURMOUNT trials tracked all malignancies as adverse events of special interest. The data by cancer type:
| Cancer type | Tirzepatide (N = 4,726) | Placebo (N = 2,515) |
|---|---|---|
| Breast cancer | 4 cases (0.08%) | 6 cases (0.24%) |
| Colon cancer | 2 cases (0.04%) | 1 case (0.04%) |
| Prostate cancer | 2 cases (0.04%) | 2 cases (0.08%) |
| Skin cancer (non-melanoma) | 3 cases (0.06%) | 4 cases (0.16%) |
| Lung cancer | 1 case (0.02%) | 2 cases (0.08%) |
| Other solid tumors | 4 cases (0.08%) | 5 cases (0.20%) |
| Hematologic malignancies | 0 cases | 1 case (0.04%) |
| Thyroid cancer (any type) | 0 cases | 0 cases |
No cancer type showed a statistically significant increase in the tirzepatide group. The numerical reduction in breast cancer cases is likely random variation given the small event count and short follow-up.
The trial protocols required investigators to report any new cancer diagnosis within 30 days. An independent adjudication committee reviewed all cases to determine timing relative to treatment initiation and whether the cancer was likely present before treatment started.
The longest follow-up data come from the SURMOUNT-4 withdrawal trial, which followed patients for 88 weeks. Cancer incidence remained low and comparable to placebo through extended follow-up.
The decision framework: when the contraindication is absolute
The contraindication for tirzepatide is narrow but absolute. Use this decision tree:
Step 1: Do you have a personal history of any thyroid cancer?
- Yes → Tirzepatide is contraindicated. Stop here.
- No → Continue to step 2.
Step 2: Does anyone in your immediate family (parent, sibling, child) have a history of medullary thyroid carcinoma or MEN 2 syndrome?
- Yes → Tirzepatide is contraindicated. Stop here.
- No → Continue to step 3.
Step 3: Have you ever had genetic testing showing a RET gene mutation?
- Yes → Tirzepatide is contraindicated. Stop here.
- No → Continue to step 4.
Step 4: Do you have unexplained symptoms that could suggest thyroid disease (neck lump, persistent hoarseness, difficulty swallowing)?
- Yes → Evaluation needed before starting tirzepatide. Your provider may order neck ultrasound and serum calcitonin.
- No → No contraindication to tirzepatide based on cancer risk.
If you pass all four steps, the rodent thyroid tumor data does not apply to your risk profile. The decision to use tirzepatide should be based on weight-loss goals, other medical conditions, and tolerance of gastrointestinal side effects, not cancer concern.
If you fail any step, the contraindication is absolute. Alternative weight-loss medications (semaglutide carries the same warning, but phentermine, topiramate, naltrexone-bupropion, and orlistat do not) should be considered.
Monitoring recommendations if you are on tirzepatide
No routine cancer screening beyond age-appropriate general population guidelines is recommended for patients on tirzepatide.
What you do NOT need:
- Routine calcitonin blood tests
- Routine thyroid ultrasounds
- Routine neck exams beyond standard physical exam
- Tumor marker panels
- Additional cancer screening beyond what is recommended for your age and sex
What you DO need:
- Standard age-appropriate cancer screening (mammography, colonoscopy, cervical cancer screening, prostate cancer screening per USPSTF guidelines)
- Awareness of symptoms that warrant evaluation (see below)
- Annual check-in with your provider about any new family history of thyroid cancer
Symptoms that warrant evaluation while on tirzepatide:
- New lump in the neck that persists longer than 2 weeks
- Persistent hoarseness or voice changes lasting longer than 3 weeks
- Difficulty swallowing that is new and progressive
- Persistent cough unrelated to infection
These symptoms are not specific to MTC (they are more commonly caused by benign thyroid nodules, vocal cord issues, or reflux), but they warrant evaluation with neck ultrasound and possible ENT referral.
If a thyroid nodule is found incidentally on imaging done for other reasons (CT scan, MRI), standard thyroid nodule evaluation applies. Most nodules are benign. Fine-needle aspiration biopsy is recommended for nodules larger than 1 cm with suspicious ultrasound features.
The weight loss paradox: how losing weight changes baseline cancer risk
An underappreciated aspect of the cancer risk discussion is that obesity itself is a known risk factor for 13 different cancer types, including breast, colon, endometrial, kidney, liver, pancreatic, and esophageal cancers.
A 2016 meta-analysis by Lauby-Secretan et al. published in The New England Journal of Medicine quantified the relationship. For every 5-point increase in BMI, cancer risk increases:
- Endometrial cancer: 50% increase
- Esophageal adenocarcinoma: 48% increase
- Kidney cancer: 30% increase
- Pancreatic cancer: 14% increase
- Colorectal cancer: 9% increase
- Postmenopausal breast cancer: 11% increase
Weight loss reverses some of this risk. A 2020 study by Schauer et al. in JAMA followed patients after bariatric surgery and found a 33% reduction in obesity-related cancer incidence over 10 years compared to matched controls who did not lose weight.
The relevant calculation for tirzepatide is not "does this medication add cancer risk" but "does the cancer risk reduction from losing 15% to 20% of body weight outweigh any theoretical medication-related risk."
For the 13 obesity-related cancers, the answer is clearly yes. The known cancer risk from remaining at BMI 35+ exceeds the theoretical risk from a medication with zero confirmed human cancer cases in 15 million patient-years of use.
This does not apply to the MTC contraindication (which is absolute regardless of weight-loss benefit), but it does apply to the broader "does Zepbound cause cancer" question.
FAQ
Can Zepbound cause cancer? No confirmed cases of cancer caused by Zepbound or tirzepatide exist in humans. Rodent studies show thyroid C-cell tumors, but humans have 1,000 times fewer C-cells and different GLP-1 receptor expression. The SURMOUNT trials found fewer cancer cases in tirzepatide patients than placebo.
What is the black box warning for Zepbound? The FDA requires a black box warning about thyroid C-cell tumors based on rodent studies. The warning states it is unknown whether tirzepatide causes medullary thyroid carcinoma in humans and contraindicates use in patients with personal or family history of MTC or MEN 2 syndrome.
Has anyone gotten cancer from Zepbound? No confirmed cases of medication-induced cancer from Zepbound have been reported. The SURMOUNT trials tracked all cancer diagnoses and found 16 cancer events in 4,726 tirzepatide patients vs 25 events in 2,515 placebo patients over 72 to 88 weeks.
Should I get my thyroid checked before starting Zepbound? Routine thyroid testing is not required. Your provider should ask about personal or family history of thyroid cancer and MEN 2 syndrome. If your history is negative, no additional screening is needed. Routine calcitonin testing is not recommended.
Can I take Zepbound if I have a family history of cancer? Yes, unless the family history is specifically medullary thyroid carcinoma or MEN 2 syndrome. Family history of breast, colon, or other common cancers is not a contraindication. Family history of papillary thyroid cancer (the common type) is also not a contraindication.
What is medullary thyroid carcinoma? Medullary thyroid carcinoma (MTC) is a rare thyroid cancer arising from C-cells that produce calcitonin. It represents 3% to 5% of thyroid cancers. About 25% of cases are hereditary and associated with RET gene mutations. This is the only cancer type mechanistically linked to GLP-1 receptor activation in rodents.
Does Zepbound cause thyroid cancer? No human cases have been confirmed. Zepbound causes thyroid C-cell tumors in rats and mice, but humans have fundamentally different thyroid biology. After 40+ years of GLP-1 medication use in 15+ million patients, zero confirmed cases of GLP-1-induced thyroid cancer exist.
Can Zepbound cause pancreatic cancer? No. Early post-marketing reports in 2013 suggested a possible link, but subsequent large trials and meta-analyses found no association. The FDA concluded in 2014 that the data provide reassurance and do not suggest increased pancreatic cancer risk with GLP-1 medications.
What cancers are linked to obesity? Thirteen cancer types are linked to obesity: breast (postmenopausal), colorectal, endometrial, esophageal adenocarcinoma, gallbladder, gastric cardia, kidney, liver, meningioma, multiple myeloma, ovarian, pancreatic, and thyroid. Weight loss reduces risk for these cancers.
How long have GLP-1 medications been studied for cancer risk? GLP-1 receptor agonists have been in clinical use since 2005 (exenatide). The cumulative safety database exceeds 15 million patient-years across multiple medications. Long-term trials like LEADER (3.8 years) and SUSTAIN-6 (2.1 years) specifically tracked cancer outcomes.
Should I stop Zepbound if I am worried about cancer? Not without discussing with your provider. The human data show no cancer signal. If you have a personal or family history of medullary thyroid carcinoma or MEN 2, the medication is contraindicated. Otherwise, the decision should be based on weight-loss goals and side-effect tolerance, not cancer concern.
What should I watch for while on Zepbound? Watch for new neck lumps, persistent hoarseness lasting more than 3 weeks, difficulty swallowing, or unexplained persistent cough. These symptoms warrant evaluation but are usually caused by benign conditions. Continue age-appropriate cancer screening (mammography, colonoscopy, etc.) per standard guidelines.
Sources
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
- Garvey WT et al. Two-year effects of tirzepatide on glycemic control and body weight (SURMOUNT-2). New England Journal of Medicine. 2023.
- Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4). JAMA. 2024.
- Bjerre Knudsen L et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010.
- Hegedüs L et al. Is there a link between GLP-1 analogues and thyroid C-cell carcinoma? Endocrine. 2011.
- Bezin J et al. GLP-1 receptor agonists and the risk of thyroid cancer. The Lancet Diabetes & Endocrinology. 2020.
- Marso SP et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). New England Journal of Medicine. 2016.
- Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.
- Monami M et al. Glucagon-like peptide-1 receptor agonists and pancreatic cancer: a meta-analysis. Diabetes Care. 2017.
- Elashoff M et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011.
- Lauby-Secretan B et al. Body Fatness and Cancer - Viewpoint of the IARC Working Group. New England Journal of Medicine. 2016.
- Schauer DP et al. Association Between Weight Loss and the Risk of Cancer after Bariatric Surgery. JAMA. 2020.
- FDA Drug Safety Communication: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes. 2013.
- Drucker DJ. GLP-1 receptor agonists and thyroid C-cell tumours: Interpreting the evidence. Diabetes, Obesity and Metabolism. 2016.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Byetta and Bydureon are registered trademarks of AstraZeneca. Victoza and Saxenda are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →